resulting from allegations that Novartis may have issued materially misleading business information to the investing public. On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) issued a …

More ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS Videos